Mangoceuticals, Inc.

Equities

MGRX

US56270V1061

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
0.2631 USD -5.10% Intraday chart for Mangoceuticals, Inc. -10.51% -4.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma MT
Mangoceuticals, Inc. announced that it expects to receive CAD 1.5 million in funding from Platinum Point Capital LLC CI
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI
Top Premarket Gainers MT
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024. CI
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024. CI
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024. CI
Mangoceuticals, Inc. Officially Launches ?PRIME? by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment CI
Mangoceuticals, Inc. Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth CI
Mangoceuticals, Inc. Accepting Pre Orders for its PRIME CI
Wall Street Set to Open Narrowly Mixed Ahead of PMI, Industrial Production Data MT
Investors Look to Keep Rally Going as US Futures Trend Higher Friday MT
Top Premarket Decliners MT
Mangoceuticals, Inc. to Introduce ?Prime?, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy Product CI
Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx CI
Wall Street Set to Open Slightly Higher; Weekly Jobless Claims Fall to Near Historic Lows MT
Top Premarket Gainers MT
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-SEP-2023. CI
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-SEP-2023. CI
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-SEP-2023. CI
Mangoceuticals, Inc. Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve CI
Mangoceuticals Partners With Greater NY Chamber of Commerce for Marketing Mango Drug Product MT
Mangoceuticals Shares Rise Following Announcement of Collaboration With RedLime Solutions MT
Chart Mangoceuticals, Inc.
More charts
Mangoceuticals, Inc. is primarily focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company has developed and is commercially marketing a new brand of erectile dysfunction (ED) products under the brand name Mango and a brand of hair loss products under the brand name Grow. These products are produced at a compounding pharmacy using a proprietary combination of United States Food and Drug Administration (FDA) approved ingredients and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. It is marketing and selling these branded ED and hair loss products exclusively online via its Website at www.MangoRx.com. Its customer platform connects consumers to licensed healthcare professionals through its Website for the provision of care via telehealth. It also owns a global patent portfolio of oral solution.
More about the company
  1. Stock Market
  2. Equities
  3. MGRX Stock
  4. News Mangoceuticals, Inc.
  5. Wall Street Set to Open Flat Amid Mixed Earnings Reports, Ahead of April PMI Data